Mississauga, ON, August 2024 – Septa Pharma Inc., a leading pharmaceutical company in Canada, has announced that it has received approval from Health Canada to import Cholestyramine, a critical medication used to lower cholesterol levels and treat itching caused by a blockage in the bile ducts of the gallbladder. This approval comes at a crucial time as Canada faces a shortage of Cholestyramine, leaving many patients without access to this essential treatment.

Addressing the Shortage
The shortage of Cholestyramine in Canada has raised significant concerns among healthcare providers and patients alike. This medication is vital for managing conditions such as hypercholesterolemia (high cholesterol) and certain liver diseases. Without access to Cholestyramine, patients are at risk of serious health complications, including an increased likelihood of heart disease and a decline in quality of life due to unmanaged symptoms.

Septa Pharma’s timely intervention will alleviate the impact of this shortage by ensuring a steady supply of Cholestyramine to pharmacies and healthcare facilities across Canada. The approval from Health Canada allows Septa Pharma to import Cholestyramine from international sources, ensuring that Canadian patients receive the medications they need without further delay.

Commitment to Patient Care
Septa Pharma has a longstanding commitment to ensuring that Canadians have access to essential medications, particularly in times of shortage. The company works closely with healthcare providers, regulatory bodies, and international suppliers to bridge gaps in the supply chain, ensuring that critical medications are available to those who need them most.

“We are pleased to receive Health Canada’s approval to import Cholestyramine and address the current shortage in Canada,” said a spokesperson for Septa Pharma. “Our primary goal is to support patients and healthcare providers by ensuring that essential medications remain accessible, especially during challenging times like these.”

Looking Forward
Septa Pharma will continue to monitor the availability of Cholestyramine and other essential medications in Canada, working proactively to prevent future shortages. The company’s efforts to import Cholestyramine are part of a broader strategy to support the Canadian healthcare system by providing reliable access to critical treatments.

About Septa Pharma
Septa Pharma Inc. is a leading pharmaceutical distributor in Canada, dedicated to improving patient care by ensuring the availability of high-quality medications. With a focus on addressing shortages and meeting the needs of the healthcare community, Septa Pharma partners with global manufacturers and regulatory bodies to deliver essential drugs to Canadian patients.

For media inquiries, please contact:

Public Relations
Septa Pharma Inc.
Email: pr@septapharma.com
Phone: +1 (905) 564-5665

Prompt Response from Septa to Address Tier 3 Shortage is Key to Minimizing Impact on Patients

Mississauga, ON — May 31, 2024 — Septa Pharma Inc., a renowned provider of critical medications in Canada, has received approval from Health Canada to import Carbamazepine Extended Release Tablets, available in 200 mg and 400 mg doses. This measure addresses the pressing shortage of this essential medication used primarily for managing epilepsy and neuropathic pain.

Septa’s swift action highlights its dedication to ensuring continuous access to high-quality medications. Leveraging a robust global network, Septa bridges the gap between demand and supply, ensuring Canadian healthcare providers have the necessary resources to deliver optimal patient care.

“Our goal is to mitigate the impact of drug shortages on Canadian communities,” states the CEO. “The approval to import Carbamazepine Extended Release Tablets underscores our commitment to patient well-being and healthcare system support during critical times.”
Through these efforts, Septa reaffirms its role as a reliable partner in healthcare, dedicated to quality, reliability, and timely solutions.

About Septa: Septa Pharma Inc. is a global healthcare conglomerate providing essential pharmaceuticals and healthcare products to enhance quality of life worldwide. For further information, visit SeptaLife.com.

For media inquires, please contact:

Public Relations
Septa Pharma Inc.
Email: pr@septapharma.com
Phone: +1 (905) 564-5665

Commitment to Quality and Reliability Drives Septa’s Efforts to Address Medication Shortages in Canada

Mississauga, ON — April 27, 2024 — Septa Pharma Inc., a leading provider of essential medications in Canada, continues to demonstrate its unwavering commitment to ensuring uninterrupted access to vital drugs with its recent approval from Health Canada to import Aminophylline inj. This approval comes as a strategic response to mitigate a critical shortage of Aminophylline, a medication used to treat respiratory conditions, within Canada.

In a landscape where access to essential medications can be unpredictable, Septa stands as a beacon of reliability and support for healthcare providers and patients alike. With a steadfast dedication to quality and safety, Septa navigates the complexities of the pharmaceutical supply chain to maintain a consistent availability of life saving medications, even during times of scarcity.

Drawing upon years of expertise and a robust network of over 200+ pharmaceutical manufacturers and sourcing partners worldwide, Septa strives to bridge the gap between demand and availability, empowering healthcare professionals to deliver optimal care to those in need. This commitment is further underscored by Septa’s understanding of the urgency of the situation and its dedication to providing timely solutions to alleviate the impact of drug shortages on Canadian communities.

The approval from Health Canada to import Aminophylline inj. exemplifies Septa’s proactive approach to addressing medication shortages. By leveraging its global network and adhering to stringent quality standards, Septa ensures that Canadian healthcare providers have access to the medications necessary to effectively treat patients.

“We recognize the importance of Aminophylline in managing respiratory conditions, and we are committed to ensuring its availability to healthcare providers across Canada,” states the CEO. “This approval reflects our ongoing efforts to prioritize the well-being of patients and support the healthcare system during challenging times.”

As Septa continues to navigate the evolving landscape of global pharmaceutical supply chain, its dedication to quality, reliability, and timely solutions remains unwavering. Through initiatives such as the importation of Aminophylline, Septa reaffirms its position as a trusted partner in healthcare, providing essential medications with integrity and compassion.

About Septa: Septa is a global healthcare and pharmaceutical conglomerate, offering health advancing products and niche services to advance and nourish the quality of life domestically and globally. For more information about Septa and its commitment to ensuring uninterrupted access to essential medications, visit www.SeptaLife.com.


For media inquiries, please contact:

Public Relations
Septa Pharma Inc.
Email: pr@septapharma.com
Phone: +1 (905) 564-5665

Septa Pharma Inc. to Participate in World Orphan Drug Congress 2024

Boston, MA — April 24, 2024 — Septa Pharma Inc., a global pharmaceutical company dedicated to addressing unmet medical needs in rare diseases, is excited to announce its attendance at the highly anticipated World Orphan Drug Congress 2024 in Boston. This premier event, renowned for its focus on orphan drugs and rare diseases, provides a valuable platform for industry collaboration, innovation, and partnership.

As an esteemed attendee, Septa looks forward to engaging with fellow participants, industry experts, and stakeholders to exchange insights, foster collaborations, and advance efforts in rare disease therapeutics. The World Orphan Drug Congress serves as a critical forum for driving progress in the development of treatments for rare and underserved conditions, aligning closely with Septa’s mission to improve patient outcomes and quality of life.

Septa recognizes the importance of forging meaningful connections and exploring potential business opportunities at events like the World Orphan Drug Congress. As such, the company welcomes inquiries from fellow attendees interested in discussing collaboration prospects, partnership opportunities, or any other mutually beneficial initiatives.

For those wishing to schedule a meeting with Septa representatives to explore potential business opportunities, please reach out via email to info@septapharma.com. Team Septa looks forward to connecting with industry peers, sharing insights, and exploring avenues for collaboration that can further advance the field of rare disease therapeutics.

“We are excited to participate in the World Orphan Drug Congress 2024 and engage with fellow stakeholders in the rare disease community,” said Team Septa. “This event provides an excellent opportunity to exchange ideas, forge partnerships, and collectively drive progress towards addressing unmet medical needs in rare diseases.”

Septa encourages all attendees of the World Orphan Drug Congress 2024 to connect with its representatives and learn more about the company’s mission, initiatives, and commitment to advancing rare disease therapeutics.

For more information about Septa and its participation in the World Orphan Drug Congress 2024, please visit www.SeptaLife.com.

For media inquiries, please contact:

Public Relations
Septa Pharma Inc.
Email: pr@septapharma.com
Phone: +1 (905) 564-5665